panitumumab,bevacizumab
takeda,roche,amgen
['cairo5', 'lba21', 'bevacizumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'panitumumab']
 cairo5 phs-iii at lba21 folfox/folfiri + bevacizumab or panitumumab #crc w liver mets -&gt; ras wt left orr 52% vs 76%, mpfs 10.6 vs 10.3mo, mdepthor 33% vs 49%, r0/1 58% vs 56% response does not translate in mpfs , resection is key 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision medicine